Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 1.00 |
| ▸ | PTGER2 | P43116 | 5/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.50 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.50 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.50 |
| ▸ | PTGFR | P43088 | 1/20 | 0.50 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4085052 | 0.99 | PTGER4 (0.98) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| Diethylamine SCHEMBL3019803 | 0.95 | PTGER4 (0.91) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL13210500 | 0.92 | PTGER4 (0.86) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL4085048 | 0.91 | PTGER4 (0.83) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL4090366 | 0.91 | PTGER4 (0.83) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL13229809 | 0.89 | PTGER4 (0.80) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL2352729 | 0.89 | PTGER4 (1.00) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL4100421 | 0.88 | PTGER4 (0.98) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| Formic Acid SCHEMBL28263353 | 0.88 | PTGER4 (0.78) | PTGER4PTGER2PTGDRTBXA2RPTGER1 | |
| SCHEMBL4085074 | 0.87 | PTGER4 (0.77) | PTGER4PTGER2PTGDRTBXA2RPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107693518-A | Purposes of the receptor antagonists of EP 4 in treatment IL 23 is disease mediated | 株式会社ＡｓｋＡｔ | 2018-02-16 | — | — | CN | claimed |
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2016-11-03 | — | — | US | claimed |
| EP-2976105-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | AskAt Inc. (JP) | 2016-01-27 | — | — | EP | claimed |
| WO-2014148053-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | ASKAT INC. (JP) | 2014-09-25 | — | — | WO | claimed |
| EP-2054401-B1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC (CA) | 2013-05-01 | — | — | EP | claimed |
| EP-2538978-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RaQualia Pharma Inc (JP) | 2013-01-02 | — | — | EP | claimed |
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2012-12-13 | — | — | US | claimed |
| CN-102770159-A | Use of EP-4 receptor antagonists for the treatment of IL-23 mediated diseases | RAQUALIA PHARMA INC | 2012-11-07 | — | — | CN | claimed |
| WO-2011102149-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2011-08-25 | — | — | WO | claimed |
| EP-4656246-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | Eisai R&D Management Co., Ltd. (JP) | 2025-12-03 | — | — | EP | disclosed |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| EP-3134085-B1 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | EISAI R&D MAN CO LTD (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4532496-A1 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2025-04-09 | — | — | EP | disclosed |
| US-12240860-B2 | Heterobicyclic carboxylic acids and salts thereof | Foshan Ionova Biotherapeutics Co., Inc. (CN) | 2025-03-04 | — | — | US | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
| EP-2054401-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | Merck Frosst Canada Ltd. (CA) | 2009-05-06 | — | — | EP | disclosed |
| WO-2009020588-A1 | PROCESS FOR MAKING THIOPHENE CARBOXAMIDE DERIVATIVE | MERCK & CO., INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008017164-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK FROSST CANADA LTD. (CA) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008017164-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK FROSST CANADA LTD. (CA) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316197-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | PTGER4, PTGER3, IL23R | PTGER4 1/4885PTGER2 6/4885PTGDR 15/4885 |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | PTGER4 190/4885PTGER2 17/4885PTGDR 163/4885 |
| US-12240860-B2 | Heterobicyclic carboxylic acids and salts thereof | PTGER4, PTGER1, GPR4 | PTGER4 1/4885PTGER2 9/4885PTGDR 24/4885 |
| US-20160317514-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF CARTILAGE DISEASE | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885PTGER2 4/4885PTGDR 11/4885 |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885PTGDR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.